JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC)

Plenary Session
© 2021 American Society of Clinical Oncology (ASCO®). All Rights Reserved.
Meeting: 2021 ASCO® ASCO Annual Meeting
Presenter: Rui-hua Xu, MD, PhD
Presentation Date: June 6, 2021
Abstract #: LBA2
Disclosures: View Disclosures

Disclaimer

This content was selected by and is provided courtesy of Your Company.

ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission.

This presentation does not necessarily represent a balanced view or full discussion of any given subject. The ideas and opinions expressed herein do not necessarily reflect those of ASCO. The authors, editors, and ASCO are not responsible for errors or omissions in translations. The mention of any company, product, service, or therapy in this collection of materials does not constitute an endorsement of any kind by ASCO. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Viewers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify, among other matters, the dosage, method, and duration of administration, or contraindications. Viewers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions.

Site provided by Springer Healthcare Limited. Part of the Springer Nature Group.

Selected content from: 2021 ASCO® Annual Meeting
JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC)
Video | Abstract | Slides

By accessing this collection you are agreeing to the following terms and conditions, and certifying that the content provided is for your personal use only.

  • The modification, adaptation, manipulation, transformation, translation or creation of derivative works based on the materials is prohibited
  • The user may not remove, obscure or modify any copyright or other notices or disclaimers included in the materials
  • The user may not transmit in any format the materials to other persons
  • Printing copies for distribution for any reason is strictly prohibited
  • The user will take all reasonable security measures necessary to prevent unauthorised duplication or unauthorised distribution of the materials
  • You accept Springer Healthcare’s Privacy Policy
© 2021 American Society of Clinical Oncology (ASCO®). All Rights Reserved.